NICE technology appraisal guidance
Issued: April 2012
TA253

Boceprevir for the treatment of genotype 1 chronic hepatitis C

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta253

1 Guidance

1.1 Boceprevir in combination with peginterferon alfa and ribavirin is recommended as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease:

  • who are previously untreated or

  • in whom previous treatment has failed.